Terns Pharmaceuticals

Our team came together for a Ternsgiving celebration, enjoying good food, great company, and taking a moment to reflect on the year’s successes.?? 2024 has been a year of incredible progress for Terns. From advancing our clinical programs in oncology and obesity to strengthening partnerships that drive innovation, we’re proud of what we’ve achieved together.? We are deeply thankful for the dedication of our team and the support of everyone who shares in our mission to address significant unmet needs. Wishing you and your loved ones a safe, joyful, and restful holiday week!?

Our CEO, Amy Burroughs, recently spoke with Ben Comer of Life Science Leader about Terns’ work and the exciting milestones ahead. At Terns, we believe the best solutions come from learning, evolving, and challenging ourselves. Our team is dedicated to advancing meaningful therapies for cancer and obesity, and it’s inspiring to see our approach recognized. As Amy shares, our ability to pivot, innovate, and embrace new opportunities has been key to our growth. We’re grateful for our talented team and the passion they bring to this journey. Read more: https://lnkd.in/ef9Y5NYj??

The momentum around novel approaches in obesity management reflects a shared commitment to enhancing care options for people worldwide.? ? Our Phase 1 study results mark a meaningful step forward in advancing our #obesity program and pioneering novel #smallmolecule therapies. We're excited to be part of the industry’s progress, working to bring new possibilities to those facing the challenges of obesity: https://lnkd.in/gUJ2Q4tb BioSpace ?

While in London for the Jefferies Global Healthcare Conference, our CEO Amy Burroughs joined BiotechTV’s Amy Brown for an interview discussing our obesity program and previewing upcoming data for our allosteric BCR-ABL program in chronic myeloid leukemia (CML).? ? Thanks for the opportunity to share our commitment to advancing potential best in class treatments for significant unmet needs.? ? To watch the full interview, visit https://lnkd.in/gV2JTMvn #JefferiesLondon

We are pleased to announce the appointment of Heather Turner, J.D., to our Board of Directors. With 25 years of strategic, operational, and legal expertise, Heather brings invaluable leadership to Terns as we continue to grow and innovate.? ? Heather’s extensive experience in #obesity and #oncology, combined with her deep understanding of all stages of therapeutic product development, will play a key role in advancing our portfolio of innovative #smallmolecule therapies targeting serious diseases, including chronic myeloid #leukemia and #obesity.? ? Welcome, Heather! For details: https://lnkd.in/ew9DwdRG

Attending the Jefferies Global Healthcare Conference 2024 in London this week? Join us today at 5 p.m. GMT for a #firesidechat featuring Amy Burroughs and Emil Kuriakose, MD, where we’ll share updates on our clinical development programs designed to address serious diseases, including #obesity and #oncology.?? ? A live webcast and #replay will be available on our website at https://ir.ternspharma.com. #JefferiesHealthcare??

Our Clinical and Medical Affairs teams had a fantastic time in San Antonio, connecting with professionals committed to advancing #obesity research and care at #ObesityWeek2024. Inspired by insightful discussions on innovative therapies, including our work with next-gen small molecule GLP-1 receptor agonists, we're more energized than ever to tackle the global challenge of obesity. A big thank you to the speakers and participants who made this event a success. Together, we're moving the needle toward transformative change in obesity care. ObesityWeek?

Our management team will participate in a #firesidechat today at 8:45 a.m. PT during the UBS Global Healthcare Conference in Rancho Palos Verdes, CA, where we'll share updates on our development programs focused on serious diseases including #oncology and #obesity. If you can’t join, a live webcast and #replay will be available on our website at https://ir.ternspharma.com.

Today we reported our financial results and provided business updates for the third quarter of 2024.? ? See our press release for details: https://lnkd.in/ebyGzRBx

#ICYMI we recently shared positive top-line results from our Phase 1 clinical trial of an investigational oral #GLP-1R agonist in healthy adults with #obesity or overweight.? These findings represent important progress in our ongoing efforts to explore innovative treatments for obesity. We are encouraged by the potential of our approach and remain focused on advancing therapies that could positively impact the lives of those affected by obesity. Check out this article from Citeline Scrip for more insights: https://lnkd.in/e7e_nWMB or read our press release for details https://lnkd.in/e6VXMJ5U